vTv Therapeutics Inc. (NASDAQ:VTVT) Receives Consensus Rating of “Moderate Buy” from Brokerages

Shares of vTv Therapeutics Inc. (NASDAQ:VTVT) have been assigned an average recommendation of “Moderate Buy” from the six ratings firms that are currently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation and five have given a buy recommendation to the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $53.00.

A number of analysts have recently weighed in on VTVT shares. Roth Mkm assumed coverage on shares of vTv Therapeutics in a report on Thursday, January 22nd. They set a “buy” rating and a $58.00 target price for the company. TD Cowen started coverage on vTv Therapeutics in a report on Monday, January 5th. They set a “buy” rating on the stock. Wall Street Zen raised vTv Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, March 14th. Evercore began coverage on vTv Therapeutics in a report on Thursday, March 12th. They issued an “outperform” rating and a $44.00 price objective for the company. Finally, HC Wainwright reissued a “buy” rating and set a $47.00 target price (up from $36.00) on shares of vTv Therapeutics in a research note on Friday, December 19th.

Institutional Trading of vTv Therapeutics

Several large investors have recently added to or reduced their stakes in VTVT. Goldman Sachs Group Inc. bought a new position in vTv Therapeutics in the 4th quarter worth $221,000. 683 Capital Management LLC bought a new stake in shares of vTv Therapeutics during the 4th quarter valued at about $731,000. Geode Capital Management LLC increased its position in shares of vTv Therapeutics by 84.3% during the fourth quarter. Geode Capital Management LLC now owns 28,194 shares of the biotechnology company’s stock valued at $1,128,000 after buying an additional 12,896 shares during the period. Finally, Baker BROS. Advisors LP increased its position in shares of vTv Therapeutics by 52.4% during the third quarter. Baker BROS. Advisors LP now owns 148,314 shares of the biotechnology company’s stock valued at $3,463,000 after buying an additional 51,000 shares during the period. Institutional investors own 17.51% of the company’s stock.

vTv Therapeutics Stock Up 5.8%

NASDAQ:VTVT opened at $38.30 on Friday. The company has a fifty day moving average of $35.52 and a 200 day moving average of $30.61. vTv Therapeutics has a 52 week low of $14.00 and a 52 week high of $44.00. The firm has a market capitalization of $150.90 million, a P/E ratio of -11.43 and a beta of 0.44.

vTv Therapeutics (NASDAQ:VTVT) last announced its quarterly earnings results on Tuesday, March 10th. The biotechnology company reported ($0.58) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.09) by $0.51. The firm had revenue of ($0.02) million during the quarter.

vTv Therapeutics Company Profile

vTv Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Westport, Connecticut, focused on discovering and developing orally administered small-molecule therapies for chronic diseases. Employing its proprietary medicinal chemistry platform, the company seeks to generate novel compounds that modulate key disease pathways while optimizing safety and pharmacokinetic properties.

The company’s lead candidate, azeliragon (TTP488), is an oral inhibitor of the receptor for advanced glycation end products (RAGE) and has completed Phase II/III clinical evaluation in early-stage Alzheimer’s disease.